https://pharmadog.xyz/news/380471 pharmadog en 2026-09-08T16:24:59.000Z Sanofi presents detailed asthma trial data while AstraZeneca reports positive COPD results at ERS 2026 https://pharmadog.xyz/news/380303 pharmadog en 2026-09-08T15:56:33.000Z Anthropic hires corporate development lead to drive biopharma acquisitions and partnerships https://pharmadog.xyz/news/380407 pharmadog en 2026-09-08T15:52:00.000Z Moonwalk Biosciences raises $70M and pivots to RNAi obesity drug development https://pharmadog.xyz/news/380304 pharmadog en 2026-09-08T15:21:33.000Z FDA finalizes Krazati withdrawal while Wegovy trial shows positive results in children 6-12 https://pharmadog.xyz/news/380239 pharmadog en 2026-09-08T14:51:43.000Z UnitedHealth executives donate heavily to Rep. Katherine Clark as No Surprises Act debate intensifies https://pharmadog.xyz/news/380219 pharmadog en 2026-09-08T14:50:38.000Z Inhibrx’s OX40 agonist plus Keytruda shows 48% response rate, beating Keytruda alone in head and neck cancer Phase 2 https://pharmadog.xyz/news/380220 pharmadog en 2026-09-08T14:31:40.000Z Structure Therapeutics reports oral GLP-1 weight-loss results comparable to Wegovy and strong Phase 1 amylin data https://pharmadog.xyz/news/380221 pharmadog en 2026-09-08T14:31:38.000Z Novo Nordisk halts two more late-stage heart failure trials, calling IL-6 an invalid target https://pharmadog.xyz/news/380122 pharmadog en 2026-09-08T14:22:31.000Z Democrats outline health-care priorities as they aim to retake House before November midterms https://pharmadog.xyz/news/380102 pharmadog en 2026-09-08T14:21:30.000Z Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILD https://pharmadog.xyz/news/380123 pharmadog en 2026-09-08T14:18:41.000Z Oura files for IPO after reporting $1.2 billion in earnings https://pharmadog.xyz/news/380078 pharmadog en 2026-09-08T14:14:32.000Z Sandoz announces $300 million biosimilar factory in Slovenia and plans to expand pipeline sevenfold https://pharmadog.xyz/news/379983 pharmadog en 2026-09-08T14:09:31.000Z FDA approves AstraZeneca's new breast cancer therapy https://pharmadog.xyz/news/380079 pharmadog en 2026-09-08T14:08:51.000Z Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapy https://pharmadog.xyz/news/379984 pharmadog en 2026-09-08T13:26:51.000Z Novartis' experimental drug fails pivotal trial for rare neuromuscular disease https://pharmadog.xyz/news/380408 pharmadog en 2026-09-08T13:23:20.000Z Novartis' del-desiran misses primary goal in late-stage myotonic dystrophy trial https://pharmadog.xyz/news/379811 pharmadog en 2026-09-08T13:00:00.000Z Consumer apps are turning to patient health records to expand services https://pharmadog.xyz/news/379835 pharmadog en 2026-09-08T12:27:28.000Z FDA approves AstraZeneca's oral SERD Etcamah for HR+/HER2-negative advanced breast cancer https://pharmadog.xyz/news/379687 pharmadog en 2026-09-08T12:05:40.000Z Novartis' $12 billion Avidity drug fails Phase 3 trial in myotonic dystrophy https://pharmadog.xyz/news/379688 pharmadog en 2026-09-08T12:01:00.000Z Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027 https://pharmadog.xyz/news/379643 pharmadog en 2026-09-08T12:00:17.000Z Moonwalk Biosciences raises $70M to advance siRNA obesity therapy https://pharmadog.xyz/news/379689 pharmadog en 2026-09-08T11:56:16.000Z Novartis' pelacarsen fails Phase 3, casting doubt on Lp(a) lowering strategy https://pharmadog.xyz/news/379707 pharmadog en 2026-09-08T11:45:00.000Z AstraZeneca’s experimental COPD drug tozorakimab cuts flare-ups by 30% in Phase 3 trials https://pharmadog.xyz/news/379708 pharmadog en 2026-09-08T11:32:23.000Z Administrative gap stalls access to new pancreatic cancer therapy https://pharmadog.xyz/news/379644 pharmadog en 2026-09-08T11:30:32.000Z Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next year https://pharmadog.xyz/news/379709 pharmadog en 2026-09-08T11:30:00.000Z Inhibrx reports promising responses to OX40 immunotherapy in HPV-positive head and neck cancer https://pharmadog.xyz/news/379559 pharmadog en 2026-09-08T11:01:00.000Z BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumor https://pharmadog.xyz/news/379535 pharmadog en 2026-09-08T11:00:53.000Z BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trial https://pharmadog.xyz/news/379536 pharmadog en 2026-09-08T11:00:21.000Z Diabetes cell-therapy firms Sernova and Seraxis announce merger https://pharmadog.xyz/news/379599 pharmadog en 2026-09-08T11:00:00.000Z BrainChild secures $116M to advance CAR-T therapies for rare pediatric brain tumors https://pharmadog.xyz/news/380279 pharmadog en 2026-09-08T10:18:00.000Z AstraZeneca’s IL-33 antibody tozorakimab earns FDA priority review after COPD trial cuts exacerbations by up to 34% https://pharmadog.xyz/news/379431 pharmadog en 2026-09-08T10:00:00.000Z Roivant's experimental pulmonary hypertension drug meets Phase 2 goals https://pharmadog.xyz/news/379367 pharmadog en 2026-09-08T10:00:00.000Z Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung disease https://pharmadog.xyz/news/380170 pharmadog en 2026-09-08T09:57:00.000Z FDA grants accelerated approval to AstraZeneca’s Etcamah, enabling ctDNA-guided therapy for HR-positive breast cancer https://pharmadog.xyz/news/380171 pharmadog en 2026-09-08T09:46:00.000Z Spyre Therapeutics reports positive Phase 2 results for anti-IL-23 antibody SPY003 in ulcerative colitis https://pharmadog.xyz/news/380054 pharmadog en 2026-09-08T09:29:00.000Z Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pending https://pharmadog.xyz/news/379894 pharmadog en 2026-09-08T09:12:00.000Z Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint https://pharmadog.xyz/news/379151 pharmadog en 2026-09-08T08:30:35.000Z Beam Therapeutics reports one-year data from early-stage AATD gene therapy trial https://pharmadog.xyz/news/379197 pharmadog en 2026-09-08T08:30:00.000Z UnitedHealth executives donate over $100,000 to Rep. Katherine Clark ahead of midterms https://pharmadog.xyz/news/379200 pharmadog en 2026-09-08T08:30:00.000Z Rural hospitals seek partnership deals as Trump Medicaid cuts threaten financial stability https://pharmadog.xyz/news/379195 pharmadog en 2026-09-08T08:30:00.000Z Reynolds launches fruit-flavored Vuse Pro vapes in Ohio despite lacking FDA authorization https://pharmadog.xyz/news/379196 pharmadog en 2026-09-08T08:30:00.000Z FDA approves Revolution Medicines’ pancreatic cancer drug Rasonque, but patients face delayed access https://pharmadog.xyz/news/379199 pharmadog en 2026-09-08T08:30:00.000Z Medical student speaks out against weight bias in clinical training https://pharmadog.xyz/news/379198 pharmadog en 2026-09-08T08:30:00.000Z Experts say gloves are unnecessary for flu shots, urging a shift to reduce waste https://pharmadog.xyz/news/379152 pharmadog en 2026-09-08T08:24:44.000Z Novartis shares tumble after late-stage failure of Avidity-acquired drug https://pharmadog.xyz/news/379786 pharmadog en 2026-09-08T08:16:00.000Z Boston Scientific recalls spinal cord implant in wake of more than 1k serious injuries https://pharmadog.xyz/news/379047 pharmadog en 2026-09-08T07:28:55.000Z Novartis' DM1 drug del-desiran misses primary endpoint in Phase 3 HARBOR trial https://pharmadog.xyz/news/378899 pharmadog en 2026-09-08T07:00:00.000Z Benelux’s strong science base eyed for biotech scaling despite funding gaps https://pharmadog.xyz/news/378515 pharmadog en 2026-09-08T04:58:00.000Z AI can transform drug discovery only when its strengths are properly leveraged https://pharmadog.xyz/news/378516 pharmadog en 2026-09-08T04:20:00.000Z Four CDMOs to watch as biopharma outsourcing grows https://pharmadog.xyz/news/378387 pharmadog en 2026-09-08T04:09:00.000Z Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale production https://pharmadog.xyz/news/378388 pharmadog en 2026-09-08T04:03:00.000Z Parkinson's drug pipeline diversifies as firms seek disease-modifying therapies https://pharmadog.xyz/news/379126 pharmadog en 2026-09-08T03:35:00.000Z Novartis' del-desiran fails primary endpoint in phase 3 Harbor trial for myotonic dystrophy type 1 https://pharmadog.xyz/news/380053 pharmadog en 2026-09-08T00:22:00.000Z Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability https://pharmadog.xyz/news/134233 pharmadog en 2026-09-07T23:04:00.000Z CLINUVEL to cut up to 20% of staff and move headquarters to New York https://pharmadog.xyz/news/376639 pharmadog en 2026-09-07T17:17:43.000Z FDA grants accelerated approval to AstraZeneca's oral SERD for breast cancer despite advisory panel opposition https://pharmadog.xyz/news/376147 pharmadog en 2026-09-07T14:48:28.000Z Novartis reports Phase 3 pelacarsen trial fails to improve cardiovascular outcomes https://pharmadog.xyz/news/379510 pharmadog en 2026-09-07T14:07:00.000Z BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer https://pharmadog.xyz/news/375639 pharmadog en 2026-09-07T11:13:52.000Z Novo Nordisk halts two cardiovascular trials of inflammation-targeting drug ziltivekimab https://pharmadog.xyz/news/375954 pharmadog en 2026-09-07T08:40:00.000Z Novo Nordisk abandons two phase 3 trials of ziltivekimab, dimming blockbuster hopes https://pharmadog.xyz/news/375043 pharmadog en 2026-09-07T07:53:43.000Z Novo Nordisk halts two late-stage ziltivekimab heart trials after futility finding https://pharmadog.xyz/news/374659 pharmadog en 2026-09-07T05:00:06.000Z Claret Capital Partners raises €575 million Fund IV to boost European biotech lending https://pharmadog.xyz/news/380278 pharmadog en 2026-09-07T03:40:00.000Z Boston Scientific cyberattack likely to have ‘material impact’ on financial results https://pharmadog.xyz/news/380292 pharmadog en 2026-09-07T02:09:00.000Z Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah https://pharmadog.xyz/news/373659 pharmadog en 2026-09-06T23:07:31.000Z ADA panel still reviewing expulsions from June conference, further actions possible